VRTX Vertex Pharmaceuticals Inc / Ma

Five-factor quant read, peer ranking, and the analyst team's own call.

6.2

composite/ 10

Factor Scores Peer Comparison Desk Analysis

Value computed

3.8

priced for 15.7% growth vs 10.3% delivered · -36% to base-case fair value

Quality computed

7.4

Piotroski 5/8 · Altman safe zone · ROE 21% · interest comfortably covered

Momentum rank

6.0

pressing its 52-week high · running hot on RSI

Defensive rank

9.0

Tactical rank

5.0

Descriptive, not predictive. Momentum, Defensive and Tactical are deciles within our liquid universe; Value and Quality are computed from filed financials. None of them forecasts a return - the model's out-of-sample AUC is published in the whitepaper. Deciles as of 2026-09-02.

Peer comparison

Composite score against sector peers · 6 names

7.8

7.7

6.4

6.2

3.9

2.2

VRTX ranks #4 of 6 · peer average 5.7

No current desk call on VRTX. The factor scores above are computed; a full analysis is four analyst desks, a bull-vs-bear debate and a risk committee, and takes about three minutes.

Run the analyst team on VRTX →

Automated, educational research - not investment advice, and not a recommendation to buy or sell any security.